Henry Schein Earnings Call Highlights Margin Momentum

Henry Schein ((HSIC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Henry Schein’s latest earnings call struck an upbeat tone, with management leaning heavily on improving underlying profitability and accelerating tech adoption. While GAAP margins dipped and cash flow was seasonally negative, non‑GAAP metrics showed solid momentum, and executives outlined a detailed multi‑year cost and growth plan that frames current headwinds as manageable rather than structural.

Broad-Based Revenue Growth Fuels a Solid Quarter

Henry Schein reported global sales of $3.4 billion, up 6.3% year over year, giving investors a reassuring top-line trajectory. Internal growth in local currencies was 2.5%, while foreign exchange added 3.1% and acquisitions contributed 0.7%, showing both organic and inorganic levers at work.

Non-GAAP Margins and Earnings Move Higher

Profitability improved on a non‑GAAP basis, with operating margin expanding 28 basis points to 7.53%. Non‑GAAP net income rose to $153 million, or $1.32 per diluted share, up from $143 million and $1.15, helped by better mix and ongoing efficiency efforts.

Adjusted EBITDA Delivers Double-Digit Growth

Adjusted EBITDA climbed to $289 million in the quarter, an 11.6% increase from $259 million a year earlier. The strong EBITDA growth compared with mid‑single‑digit revenue gains underscores operating leverage from cost controls and higher-margin business lines.

High-Growth Segments Take a Larger Profit Share

U.S. dental operations, global technology, and value‑added services were standouts, with Global Tech sales up 7.0% and value‑added services up 10.6% (7.8% in local currencies). Management noted these higher-growth, higher-margin areas are nearing half of total operating income and are on track to exceed 50% by 2027.

Cloud Software Becomes a Core Growth Engine

Cloud and software momentum remained strong, with cloud-based customers rising roughly 25% year over year to more than 13,000 Dentrix Ascend and Dentally subscribers. These platforms, along with other software lines, delivered robust revenue growth, pointing to a stickier, recurring revenue base over time.

E-Commerce Platform Rollout Accelerates Digital Shift

The company highlighted rapid digital adoption, with over 80% of U.S. dental e‑commerce sales now running through henryschein.com. Rollouts in Canada and U.S. labs are complete, and management expects the broader U.S. rollout to finish by the end of August, which should further streamline ordering and logistics.

Share Repurchases Signal Confidence and Capital Discipline

Henry Schein returned capital to shareholders by repurchasing about 1.6 million shares in the quarter at an average price of $77.64, totaling $125 million. The company still has roughly $655 million remaining under its authorization, giving it ample flexibility to continue buybacks alongside growth investments.

Value-Creation Program Starts to Take Hold

Management reaffirmed its goal of more than $200 million in annual operating income improvement over the coming years, targeting a $125 million run rate by the end of 2026. Early actions include outsourcing some back‑office work, indirect procurement savings, value‑based pricing, and building corporate brand leverage, all aimed at structurally boosting margins.

GAAP Earnings Lag as Restructuring Weighs

On a GAAP basis, operating margin slipped 12 basis points to 5.41%, and net income declined to $107 million from $110 million. The gap versus non‑GAAP results reflects restructuring charges and other items that are hitting near‑term earnings even as underlying profitability trends improve.

Seasonal Working Capital Drives Negative Cash Flow

Operating cash flow was negative $97 million in the quarter, driven mainly by lower accounts payable and accrued expenses. Management framed this as seasonal and reiterated that for the full year, operating cash flow is expected to exceed net income, suggesting no change to the broader cash generation story.

Medical Segment Hit by Mild Flu Season

The medical business faced weakness in point‑of‑care diagnostic tests for respiratory illnesses after a light flu season. Since this category represents roughly 15% to 20% of medical sales, it dragged on reported growth; excluding it, medical sales would have posted mid‑single‑digit gains.

Digital Equipment Faces Pricing Pressure

Digital equipment sales were essentially flat as competitive pressure, especially in intraoral scanners, pushed down average selling prices. Higher unit volumes were not enough to offset lower prices, which constrained top-line growth and highlighted intensifying competition in certain technology niches.

Implant Mix Shift Squeezes Gross Margins

Specialty products sales increased 8.1% (1.7% in local currencies), with value implants posting high single-digit growth. However, a mix shift away from premium implants toward value offerings weighed on gross margins compared with last year, reflecting customers’ price sensitivity.

Restructuring Costs Cloud GAAP Outlook

The company recorded $12 million of restructuring expenses in the quarter, equivalent to $0.07 per diluted share, as part of its value-creation drive. Because restructuring costs are still being evaluated, management declined to provide GAAP guidance, focusing investors instead on non‑GAAP metrics.

Macro Cost Risks from Oil and Freight

Rising oil prices pose a risk to freight and overall cost inflation, a concern the company addressed directly on the call. Management believes its mitigation plans can offset these pressures under current assumptions but cautioned that a sharper move higher in oil could become a tipping point.

Remeasurement Gains Add Noise to Quarterly EPS

First-quarter results included an $11 million remeasurement gain tied to gaining control of S.I.N. 360, worth about $0.07 per share. Management told investors that such gains are inherently uncertain and expects them to be smaller in 2026 than in 2025, reinforcing that these items should not drive long‑term valuation.

Guidance Reinforces Steady Growth and Margin Plans

Management reaffirmed 2026 non‑GAAP guidance for sales growth of about 3% to 5% versus 2025 and non‑GAAP diluted EPS of $5.23 to $5.37, assuming a roughly 24% tax rate. Adjusted EBITDA is projected to grow in the mid‑single digits from a $1.1 billion base, with value‑creation savings weighted toward the back half of 2026 and assumptions of stable end markets and manageable oil and tariff impacts.

Henry Schein’s call painted a picture of a business leaning into technology, services, and structural cost improvements while absorbing near-term margin and cash flow noise. For investors, the story is one of steady growth, expanding non‑GAAP profitability, and disciplined capital returns, tempered by macro risks and execution demands on its ambitious value‑creation program.